Status: Not yet recruiting

EFG vs IVIG in TAMG

This study is a prospective, multi-center, randomized controlled study to evaluate the efficacy and safety of efgartigimod (EFG) and intravenous immunoglobulin (IVIG) in the perioperative application for acetylcholine receptor (AChR) antibody-positive thymoma patients with myasthenia gravis in order to provide reliable evidence for clinical decision-making.

Participants needed: 64

Trial details

Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Zhongshan HospitalUpdated: Nov 17, 2025Locations: 1

Eligibility criteria

Patients aged >18 years and ≤75 years, with an expected survival time >12 months... [+7]

MGFA type V; [+15]

Status: Recruiting

Seronegative Myasthenia Gravis - Efgartigimod IV

This is to study the efficacy, safety and tolerability of efgartigimod in patients with seronegative generalized myasthenia gravis. This is an open label study. There will be 30 participants to enroll at University Health Network Toronto General Hospital. Study duration is 43 weeks from screening to end of study.

Participants needed: 30

Trial details

Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: University Health Network, TorontoUpdated: Sep 19, 2024Locations: 1

Eligibility criteria

Evidence of signed and dated informed consent document(s) indicating that the su... [+12]

Patients who discontinued early from trials of efgartigimod for pregnancy or res... [+12]